Posted by Michael Wonder on 30 Jun 2026
AbbVie receives positive CHMP opinion for upadacitinib (Rinvoq) for the treatment of adults and adolescents with non-segmental citiligo
29 June 2026 - Positive CHMP opinion is supported by data from the Phase 3 Viti-Up clinical studies, in which upadacitinib achieved both co-primary endpoints demonstrating at least a 50% improvement in total body repigmentation (T-VASI 50) and at least a 75% improvement in facial repigmentation (F-VASI 75) from baseline at week 481
AbbVie today announced that the EMA's CHMP has adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo.
